ABSTRACT
BACKGROUND: Industry payments to US cancer centers are poorly understood. METHODS: US National Cancer Institute (NCI)-designated comprehensive cancer centers were identified (n = 51). Industry payments to NCI-designated comprehensive cancer centers from 2014 to 2021 were obtained from Open Payments and National Institutes of Health (NIH) grant funding from NIH Research Portfolio Online Reporting Tools (RePORT). Given our focus on cancer centers, we measured the subset of industry payments related to cancer drugs specifically and the subset of NIH funding from the NCI. RESULTS: Despite a pandemic-related decline in 2020-2021, cancer-related industry payments to NCI-designated comprehensive cancer centers increased from $482 million in 2014 to $972 million in 2021. Over the same period, NCI research grant funding increased from $2â481â million to $2â724â million. The large majority of nonresearch payments were royalties and licensing payments. CONCLUSION: Industry payments to NCI-designated comprehensive cancer centers increased substantially more than NCI funding in recent years but were also more variable. These trends raise concerns regarding the influence and instability of industry payments.
Subject(s)
Cancer Care Facilities , Drug Industry , National Cancer Institute (U.S.) , National Institutes of Health (U.S.) , Research Support as Topic , United States , Humans , National Cancer Institute (U.S.)/economics , Drug Industry/economics , Drug Industry/trends , Research Support as Topic/trends , Research Support as Topic/economics , National Institutes of Health (U.S.)/economics , Cancer Care Facilities/economics , Conflict of Interest/economics , Antineoplastic Agents/economics , Neoplasms/economicsABSTRACT
This study evaluates the characteristics of generic active pharmaceutical ingredients (APIs) used to manufacture drugs with shortages in the US and facilities producing APIs worldwide.
Subject(s)
Bulk Drugs , Drug Industry , Drugs, Generic , Bulk Drugs/economics , Bulk Drugs/supply & distribution , Drug Industry/economics , Drug Industry/statistics & numerical data , Drug Industry/trends , Drugs, Generic/economics , Drugs, Generic/supply & distribution , United States , InternationalitySubject(s)
Drug Industry , RNA, Circular , Humans , Drug Industry/methods , Drug Industry/trends , mRNA Vaccines , RNA, Circular/therapeutic useABSTRACT
Amid the modernization and internationalization of traditional Chinese medicine(TCM), the safety of TCM has attracted much attention. At the moment, the government, scientific research teams, and pharmaceutical enterprises have made great efforts to explore methods and techniques for clinical safety evaluation of TCM. Although considerable achievements have been made, there are still many problems, such as the non-standard terms of adverse reactions of TCM, unclear evaluation indicators, unreasonable judgment methods, lack of evaluation models, out-of-date evaluation standards, and unsound reporting systems. Therefore, it is urgent to further deepen the research mode and method of clinical safety evaluation of TCM. Based on the current national requirements for the life-cycle management of drugs, this study focused on the problems in the five dimensions of clinical safety evaluation of TCM, including normative terms, evaluation modes, judgment methods, evaluation standards, and reporting systems, and proposed suggestions on the development of a life-cycle clinical safety evaluation method that conformed to the characteristics of TCM, hoping to provide a reference for future research.
Subject(s)
Drug Evaluation , Medicine, Chinese Traditional , Medicine, Chinese Traditional/standards , Drug Evaluation/methods , Drug Evaluation/standards , Drug Evaluation/trends , Drug Industry/standards , Drug Industry/trends , Research/standards , Research/trends , HumansABSTRACT
La pandemia por COVID-19 ha afectado gravemente a la dinámica de los sistemas de salud y ha tenido consecuencias muy negativas en la atención sanitaria. Sin embargo, ha impulsado en mayor o menor medida la transformación digital en muchos centros sanitarios y en la industria farmacéutica. En este artículo se revisa la experiencia de la transformación digital derivada de la pandemia desde la perspectiva de los profesionales sanitarios y de la industria farmacéutica, con énfasis en la teleconsulta, en la formación a distancia y en el modelo de interacción entre sanitarios e industria. Además, se dan algunas claves para llevar a cabo una transformación digital exitosa (AU)
The COVID-19 pandemic has affected healthcare systems severely and has had a negative impact on healthcare. However, it has also been a catalyst for digital transformation in many healthcare centers and in the pharmaceutical industry. In this article, the experience of digital transformation during the pandemic is reviewed from the perspective of healthcare professionals and the pharmaceutical industry, with a focus on digital visits, on-line education, and the model of interaction between healthcare professionals and the industry. Also, some key points are given to facilitate a successful digital transformation (AU)
Subject(s)
Humans , Drug Industry/trends , Remote Consultation , Health Personnel , Coronavirus Infections , PandemicsABSTRACT
The origin of small-molecule leads that were pursued across the independent research organizations Roche and Genentech from 2009 to 2020 is described. The identified chemical series are derived from a variety of lead-finding methods, which include public information, high-throughput screening (both full file and focused), fragment-based design, DNA-encoded library technology, use of legacy internal data, in-licensing, and de novo design (often structure-based). The translation of the lead series into in vivo tool compounds and development candidates is discussed as are the associated biological target classes and corresponding therapeutic areas. These analyses identify important trends regarding the various lead-finding approaches, which will likely impact their future application in the Roche and Genentech research groups. They also highlight commonalities and differences across the two independent research organizations. Several caveats associated with the employed data collection and analysis methodologies are included to enhance the interpretation of the presented information.
Subject(s)
Drug Discovery/trends , Drug Industry/trends , Pharmacology/trends , Small Molecule Libraries , DNA/chemistry , DNA/genetics , High-Throughput Screening Assays , Humans , Research DesignABSTRACT
The nutraceutical market is currently a high-impact multi-billion-dollar industry, and it is anticipated to grow rapidly over the next decade. Nutraceuticals comprise diverse food-derived product categories that have become widespread due to increased consumer awareness of potential health benefits and the need for improved wellness. This targeted review is designed to identify the current global trends, market opportunities, and regulations that drive the nutraceutical industry. Safety and efficacy concerns are also explored with a view to highlighting areas that necessitate further research and oversight. Key drivers of the nutraceutical market include aging populations, consumer awareness, consumer lifestyle, increasing cost of healthcare, and marketing channels. Although some nutraceuticals hold promising preventive and therapeutic opportunities, there is a lack of a universal definition and regulatory framework among countries. Moreover, there is a lack of adequate evidence for their efficacy, safety, and effectiveness, which was even further highlighted during the ongoing coronavirus pandemic. Future prospective epidemiological studies can delineate the health impact of nutraceuticals and help set the scientific basis and rationale foundation for clinical trials, reducing the time and cost of trials themselves. Together, an understanding of the key drivers of the nutraceutical market alongside a consistent and well-defined regulatory framework will provide further opportunities for growth, expansion, and segmentation of nutraceuticals applications.
Subject(s)
Biological Products/therapeutic use , Dietary Supplements , Drug Industry/trends , Food Industry/trends , Animals , Biological Products/adverse effects , Commerce , Consumer Product Safety , Dietary Supplements/adverse effects , Drug Approval , Drug Industry/legislation & jurisprudence , Food Industry/legislation & jurisprudence , Humans , Legislation, Food/trends , Risk AssessmentABSTRACT
Proposals to waive intellectual property rights (IPRs) on coronavirus 2019 (COVID-19)-related developments have gained considerable support among politicians, including from US President Biden, academics, nongovernmental organizations (NGOs), the media, and the general public. However, there are surprisingly few reflections about the short- and long-term consequences for medical innovation, particularly the development of new drugs and vaccines. In this feature, I reflect on the consequences for innovative entrepreneurial companies, the incentives to innovate, and consequences for international knowledge flows to low- and middle-income countries. I conclude that waiving IPRs reduces opportunities for entrepreneurial companies to attract sufficient funding for developing medical innovations. Low- and middle-income countries might suffer reduced knowledge inflows in the absence of IPRs that undermine their ability to develop medical innovations.
Subject(s)
Drug Discovery , Drug Industry/trends , Intellectual Property , Antiviral Agents/pharmacology , Antiviral Agents/therapeutic use , COVID-19 Vaccines/therapeutic use , Developing Countries , Drug Industry/legislation & jurisprudence , Humans , COVID-19 Drug TreatmentABSTRACT
The growth in drug development over the past years reflects significant advancements in basic sciences and a greater understanding of molecular pathways of disease. Benchmarking industry practices has been important to enable a critical reflection on the path to evolve pharmaceutical testing, and the outcome of past industry surveys has had some impact on best practices in testing. A survey was provided to members of SPS, ACT, and STP. The survey consisted of 37 questions and was provided to 2550 participants with a response rate of 24%. Most respondents (â¼75%) came from the US and Europe. The survey encompassed multiple topics encountered in nonclinical testing of pharmaceuticals. The most frequent target indications were oncology (69%), inflammation (55%), neurology/psychiatry/pain (46%), cardiovascular (44%), and metabolic diseases (39%). The most frequent drug-induced toxicology issues confronted were hepatic, hematopoietic, and gastrointestinal. Toxicological effects that impacted the no observed adverse effect level (NOAEL) were most frequently based on histopathology findings. The survey comprised topics encountered in the use of biomarkers in nonclinical safety assessment, most commonly those used to assess inflammation, cardiac/vascular, renal, and hepatic toxicity as well as common practices related to the assessment of endocrine effects, carcinogenicity, genotoxicity, juvenile and male-mediated developmental and female reproductive toxicity. The survey explored the impact of regulatory meetings on program design, application of the 3 Rs, and reasons for program delays. Overall, the survey results provide a broad perspective of current practices based on the experience of the scientific community engaged in nonclinical safety assessment.
Subject(s)
Drug Evaluation, Preclinical/standards , Drug Industry/standards , Drug Industry/trends , Guidelines as Topic , Pharmaceutical Preparations/standards , Toxicity Tests/standards , Toxicity Tests/trends , Drug Evaluation, Preclinical/methods , Drug Industry/methods , Forecasting , Humans , Surveys and Questionnaires , Toxicity Tests/methods , United StatesABSTRACT
The medical affairs function represents one of the scientific interfaces in a pharmaceutical organization. Over the last two decades, medical affairs has evolved from being a support function to a strategic pillar within organizational business units. The COVID-19 pandemic has given rise to unforeseen circumstances resulting in a dramatic change in external stakeholder engagements, catapulting the medical affairs function into leading the way on scientific engagements and patient-centric endeavors. The changes in stakeholder interactions and behavior as a result of the pandemic last year are likely to persist in the foreseeable future for which medical affairs professionals need to enhance existing skill sets and acquire expertise in newer domains. In this paper, the transformation of the medical affairs team to a key strategic partner and the skills required to strengthen this transition, in the next normal of a post-COVID world, is explored.
Subject(s)
COVID-19/prevention & control , Drug Development/trends , Drug Industry/trends , Stakeholder Participation , COVID-19/epidemiology , Communicable Disease Control/standards , Drug Development/organization & administration , Drug Development/standards , Drug Industry/organization & administration , Drug Industry/standards , Health Services Accessibility/standards , Humans , India , Pandemics/prevention & controlABSTRACT
Delivering transformative therapies to patients while maintaining growth in the pharmaceutical industry requires an efficient use of research and development (R&D) resources and technologies to develop high-impact new molecular entities (NMEs). However, increasing global R&D competition in the pharmaceutical industry, growing impact of generics and biosimilars, more stringent regulatory requirements, as well as cost-constrained reimbursement frameworks challenge current business models of leading pharmaceutical companies. Big data-based analytics and artificial intelligence (AI) approaches have disrupted various industries and are having an increasing impact in the biopharmaceutical industry, with the promise to improve and accelerate biopharmaceutical R&D processes. Here, we systematically analyze, identify, assess, and categorize key risks across the drug discovery and development value chain using a new risk map approach, providing a comprehensive risk-reward analysis for pharmaceutical R&D.